, data was analyzed from the REMICADE 5 mg/kg every eight week maintenance arm of each trial, the only regimen common to both EXPRESS and EXPRESS II. At week 10, after infusions at weeks 0, 2, and 6, the proportions of patients achieving PASI 75 were 80 percent versus three percent of placebo patients for EXPRESS and 75 percent versus two percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). At week 10, the proportions of patients achieving PASI 90, or nearly complete skin clearance, were 57 percent versus one percent of placebo patients for EXPRESS and 45 percent versus 0.5 percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). PASI 75 responses achieved at week 10 were maintained through week 26 in both EXPRESS and EXPRESS II (81 percent and 78 percent of patients achieved at least PASI 75 improvement from baseline, respectively), and the majority of patients achieved PASI 75 at week 50 in the REMICADE 5 mg/kg every eight-week maintenance groups.
"These data show great potential for REMICADE in the treatment of a disease that often carries great physical and emotional challenges," said Robert Matheson, MD, Oregon Medical Research Center, and study investigator. "The potential of achieving nearly complete skin clearance is exciting and holds great promise for patients with this difficult to treat disease."
Investigators reported that at week 10 patients in both EXPRESS and EXPRESS II receiving REMICADE experienced improvements in the Dermatology Life Quality Index (DLQI) and Physician's Global Assessment (PGA), measures of quality of life and psoriasis severity, respectively. In both studies, following 5 mg/kg induction therapy, REMICADE-treated patients experienced a median improvement of nine points in DLQI, a change that is considered to be a clinically meaningful decrease in psoriasis-related burden for the patient, compared to no improvement for placebo patients (REMICADE vs. placebo, -9.0 vePage: 1 2 3 Related biology news :1
Contact: Michael Parks
. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients2
. Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis3
. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer4
. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID5
. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial6
. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease7
. Phase III trials of cellulose sulfate microbicide for HIV prevention closed8
. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening9
. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants10
. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis11
. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA